Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
Seeks partnership between government and private medical colleges for providing superior medical education
MVUs will provide diagnosis treatment, vaccination, artificial insemination, minor surgical interventions, audio-visual aids and extension services to farmers/animal owners at their doorstep in far flung areas.
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Acquisitions have the potential to add at least $1 billion in sales by 2028
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
Subscribe To Our Newsletter & Stay Updated
